Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84829 trials found · Page 38 of 4242
-
Breakthrough trial tests new drug that could transform breast cancer treatment
Disease control Recruiting nowThis study is a multicenter, randomized, open-label, parallel Phase III clinical trial. 650 early-stage or locally advanced breast cancer participants will be enrolled and randomly assigned to SHR-A1811 monotherapy group (trial group) or TCbHP treatment group (control group) at a…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New hope for tough pancreatic cancer: experimental drug targets specific genetic weakness
Disease control Recruiting nowThe purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreati…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Major trial tests promising new weapon against ovarian cancer
Disease control Recruiting nowThis is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-b…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
One-Shot gene therapy tested in boys with devastating muscle disease
Disease control Recruiting nowThis is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety o…
Phase: PHASE3 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Apr 23, 2026 08:59 UTC
-
New drug combo battles advanced lung cancer in major trial
Disease control Recruiting nowThis study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC
-
Scientists test re-engineered immune cells to fight stomach cancer
Disease control Recruiting nowTo evaluate the efficacy of CT041 in sequential treatment after first-line treatment of advanced gastric/esophagogastric junction adenocarcinoma
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New stroke treatment could extend critical window for recovery
Disease control Recruiting nowThis randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human tenecteplase (rhTNK-tPA) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known wel…
Phase: PHASE3 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Apr 23, 2026 08:58 UTC
-
High-Fat diet tested as emergency treatment for worst seizures
Disease control Recruiting nowThe purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).
Phase: NA • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New brain cancer drug enters major final trial
Disease control Not yet recruitingThis phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by dam…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC
-
Brain injection targets root cause of Parkinson's in groundbreaking trial
Disease control Recruiting nowParkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings. Pathological aggregation of α-synuclein and the consequent death of dopaminergic neurons are the primary …
Phase: PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New pill could ease strict diet for PKU patients
Disease control Recruiting nowThe goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignme…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New hope for advanced cervical cancer: major trial tests drug combo
Disease control Recruiting nowThis study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Phase: PHASE3 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New Triple-Drug attack on Tough-to-Treat blood cancer shows early promise
Disease control Recruiting nowVenetoclax can bind to the BCL-2 protein, thereby initiating the apoptosis program and exerting anti-AML effects. The induction regimen combining venetoclax with hypomethylating agents (HMA) significantly improves the remission rate (over 60%) in elderly unfit AML patients and ma…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Breakthrough trial aims to slash TB treatment time in half
Disease control Recruiting nowThis study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drug…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
Major trial aims to stop fatty liver disease from turning deadly
Disease control Recruiting nowThe main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
Gene therapy breakthrough tested in World's poorest regions for devastating muscle disease
Disease control Recruiting nowThe study objective is to determine the real-world safety and effectiveness of Vesemnogene lantuparvovec for the treatment of SMA. The specific objectives are: * To determine clinical effectiveness of Vesemnogene lantuparvovec therapy for SMA as evaluated by developmental gross…
Phase: PHASE3 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
Could a basic brain scan unlock life-saving stroke care worldwide?
Disease control Recruiting nowThe DONE SYMPLE Investigator-initiated phase III prospective, randomized, open-label, blinded endpoint-controlled clinical trial. This clinical trial is a global clinical study testing whether a procedure called endovascular therapy, which removes blood clots from blocked brain …
Phase: NA • Sponsor: Santiago Ortega Gutierrez • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Weekly shot aims to shed pounds in major new obesity trial
Disease control Recruiting nowThis is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a rati…
Phase: PHASE3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New 'Living Drug' trial targets tough blood cancers
Disease control Not yet recruitingThis study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New 'Living Drug' trial targets Tough-to-Treat blood cancer
Disease control Not yet recruitingThis study is a single-arm, single-center clinical study, with the main purpose of IIT clinical trials to evaluate the safety and initial efficacy of BCMA-GPRC5DCAR-T cells in subjects with relapsed/refractory multiple myeloma (r/rMM). The dose of this study was set to 2.0×106/kg…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC